Bibliography
1. Xu J, Gao F, Yuan Z, Jiang L, Xia Z, Zhao Z. Mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) associated with bacteria meningitis caused by listeria monocytogenes: A case report. Medicine (Baltimore). 2018 Jul;97(30):e11561. doi: 10.1097/MD.0000000000011561. PMID: 30045281; PMCID: PMC6078722.
2. Abenhaim Halpern L, Agyeman P, Steinlin M, El-Koussy M, Grunt S. Mild encephalopathy with splenial lesion and parainfluenza virus infection. Pediatr Neurol 2013;48:252—4
3 Mustafa KN, Qasem U, Al-Ryalat NT, Bsisu IK. Rituximab-associated posterior reversible encephalopathy syndrome. Int J Rheum Dis. 2019 Jan;22(1):160-165. doi: 10.1111/1756-185X.13427. Epub 2018 Nov 5. PMID: 30398015.
4. Kurokawa Y, Masuda H, Kobayashi T, Ono H, Kato H, Imadome KI, Abe J, Abe Y, Ito S, Ishiguro A. Effective therapy with infliximab for clinically mild encephalitis/encephalopathy with a reversible splenial lesion in an infant with Kawasaki disease. Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(3):190-195. Japanese. doi: 10.2177/jsci.40.190. PMID: 28747606.
5. Fong CY, Khine MM, Peter AB, Lim WK, Rozalli FI, Rahmat K. Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) due to dengue virus. J Clin Neurosci 2017;36:73–75
6. Fang Q, Chen L, Chen Q, Lin Z, Yang F. Clinically mild encephalitis/ encephalopathy with a reversible splenial lesion of corpus callosum in Chinese children. Brain Dev 2017;39(04):321–326
7. Kosami K, Kenzaka T, Sagara Y, Minami K, Matsumura M. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion caused by methicillin-sensitive Staphylococcus aureus bacteremia with toxic shock syndrome: a case report. BMC Infect Dis 2016;16:160
8. Jinnai A, Kikuchi T, Ishikawa M, Nishimura Y, Shibata K, Sakura H. [A case of rubella encephalitis presenting as clinically mild encephalitis/encephalopathy with a reversible splenial lesion] [Article in Japanese]. Rinsho Shinkeigaku 2014;54(08):668–670
9. Man BL, Fu YP. The first case of mild encephalopathy with a reversible splenial lesion due to Japanese encephalitis virus infection. BMJ Case Rep 2013;2013:bcr2013200988
10. Chen WX, Liu HS, Yang SD, et al. Reversible splenial lesion syndrome in children: Retrospective study and summary of case series. Brain Dev 2016;38(10):915–927
11. Kakadia B, Ahmed J, Siegal T, Jovin TG, Thon JM. Mild encephalopathy with reversible splenium lesion (MERS) in a patient with COVID-19. J Clin Neurosci. 2020;79:272-274. doi:10.1016/j.jocn.2020.07.009
12. Bektaş G, Akçay N, Boydağ K, Şevketoğlu E. Reversible splenial lesion syndrome associated with SARS-CoV-2 infection in two children. Brain Dev. 2021 Feb;43(2):230-233. doi: 10.1016/j.braindev.2020.10.002. Epub 2020 Oct 13. PMID: 33082059; PMCID: PMC7553133.
13. Robert M Conry, Joseph C Sullivan , Louis B Nabors. Ipilimumab-induced encephalopathy with a reversible splenial lesion Cancer Immunol Res . 2015 Jun;3(6):598-601.
14. Takanashi J, Shiihara T, Hasegawa T, Takayanagi M, Hara M, Okumura A, Mizuguchi M.Takanashi J, et al. J. A case of clinically mild encephalitis with a reversible splenial lesion (MERS) after mumps vaccination Neurol Sci. 2015 Feb 15;349(1-2):226-8.
15. Tuscano A, Zoppo M, Canavese C, Cogoni M, Scolfaro C. Transient blindness associated with mild encephalitis/encephalopathy with a reversible splenial lesion (MERS): a case report and review of literature. Ital J Pediatr. 2020 Oct 12;46(1):152. doi: 10.1186/s13052-020-00918-0. PMID: 33046117; PMCID: PMC7552542.
16 Tetsuka S. Reversible lesion in the splenium of the corpus callosum. Brain Behav. 2019 Nov;9(11):e01440. doi: 10.1002/brb3.1440. Epub 2019 Oct 6. PMID: 31588684; PMCID: PMC6851813.
17 Takanashi J. Two newly proposed infectious encephalitis/encephalopathy syndromes. Brain Dev 2009;31:521–8.
18 Tada, H., Takanashi, J., Barkovich, A. J., Oba, H., Maeda, M., Tsukahara, H., Kohno, Y. (2004). Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology, 63(10), 1854–1858. https ://doi.org/10.1212/01.WNL.0000144274.12174.CB
19 Yuan, J., Yang, S., Wang, S., Qin, W., Yang, L., & Hu, W. (2017). Mild en‐ cephalitis/encephalopathy with reversible splenial lesion (MERS) in adults‐a case report and literature review. BMC Neurology, 17(1), 103. https://doi.org/10.1186/s12883-017-0875-5
20 Zhang, S., Ma, Y., & Feng, J. (2015). Clinicoradiological spectrum of re‐ versible splenial lesion syndrome (RESLES) in adults: A retrospective study of a rare entity. Medicine (Baltimore), 94(6), e512. https://doi. org/10.1097/MD.0000000000000512
21 Y ıld ız AE, Mara ş Genç H, Gürka ş E, Akmaz Ünlü H, Öncel İH, Güven A. Mild encephalitis/encephalopathy with a reversible splenial lesion in children. Diagn Interv Radiol. 2018;24(2):108 –12.
22 Miyata, R., Tanuma, N., Hayashi, M., Imamura, T., Takanashi, J.‐I., Nagata, R., … Kubota, M. (2012). Oxidative stress in patients with clinically mild encephalitis/encephalopathy with a reversible splenial le‐ sion (MERS). Brain and Development, 34(2), 124–127. https://doi. org/10.1016/j.braindev.2011.04.004
23 Motobayashi, M., Fukuyama, T., Okuno‐Yuguchi, J., Tsukahara, K., Nagaharu, S., Hagimoto, R., … Inaba, Y. (2017). Subclinical neuroaxo‐ nal damage in patients with clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Pediatric Neurology, 74, e3–e4. https:// doi.org/10.1016/j.pediatrneurol.2017.05.026
24 Kaminski, J. A., & Prüss, H. (2019). N‐methyl‐d‐aspartate receptor en‐ cephalitis with a reversible splenial lesion. European Journal of Neurology, 26(6), e68–e69
25 Starkey, J., Kobayashi, N., Numaguchi, Y., & Moritani, T. (2017). Cytotoxic lesions of the corpus callosum that show restricted diffusion: Mechanisms, causes, and manifestations. Radiographics, 37(2), 562– 576. https://doi.org/10.1148/rg.2017160085
26. Engelbrecht V, Scherer A, Rassek M, Witsack HJ, Mödder U. Diffusionweighted MR imaging in the brain in children: findings in the normal brain and in the brain with white matter diseases 1. Radiology. 2002;222:410–8.
27. Phillips MD, McGraw P, Lowe MJ, Mathews VP, Hainline BE. Diffusionweighted imaging of white matter abnormalities in patients with phenylketonuria. Am J Neuroradiol. 2001;22:1583–6.
28 Starkey, J., Kobayashi, N., Numaguchi, Y., & Moritani, T. (2017). Cytotoxic lesions of the corpus callosum that show restricted diffusion: Mechanisms, causes, and manifestations. Radiographics, 37(2), 562– 576. https://doi.org/10.1148/rg.2017160085
29 Garcia‐Monco, J. C., Cortina, I. E., Ferreira, E., Martínez, A., Ruiz, L., Cabrera, A., & Beldarrain, M. G. (2011). Reversible splenial lesion syndrome (RESLES): What’s in a name? Journal of Neuroimaging, 21(2), e1–e14. https://doi.org/10.1111/j.1552-6569.2008.00279.x
30 Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435‐445.
31 Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS One. 2017;12(9):e0183844. Published 2017 Sep 15. doi:10.1371/journal.pone.0183844
32. Kulkarni HS, Kasi PM. Rituximab and cytokine release syndrome. Case Rep Oncol. 2012;5(1):134‐141.
33. Seifert G, Reindl T, Lobitz S, Seeger K, Henze G. Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature. Haematologica. 2006;91(6 Suppl):Ecr23.
34. Chou WC, Ko BS, Tien HF. Severe pulmonary complications after initial treatment with Rituximab for the Asian‐variant of intravascu‐ lar lymphoma. Haematologica. 2007;92(1):141‐142.
35. Bienvenu J, Chvetzoff R, Salles G, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treat‐ ment. Hematol J. 2001;2(6):378‐384.
36. Obeid T, Awada A. Posterior leukoencephalopathy without se‐ vere hypertension: utility of diffusion‐weighted MRI. Neurology. 1999;53(6):1372‐1373.
37 Provenzale JM, Petrella JR, Cruz LC Jr, Wong JC, Engelter S, Barboriak DP. Quantitative assessment of diffusion abnormali‐ ties in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2001;22(8):1455‐1461.
38. Focosi D, Tuccori M, Maggi F. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab. Rev Med Virol. 2019 Nov;29(6):e2077. doi: 10.1002/rmv.2077. Epub 2019 Aug 1. PMID: 31369199.
39. Sáenz-Farret M, Cansino-Torres MA, Sandoval-Rodríguez V, Navarro-Ibarra R, Zúñiga-Ramírez C. The Spectrum of Acute Disseminated Encephalomyelitis and Mild Encephalopathy with Reversible Splenial Lesion. Case Rep Neurol Med. 2019 Oct 17;2019:9272074. doi: 10.1155/2019/9272074. PMID: 31781440; PMCID: PMC6855051.
40. Makuuchi Y, Nishimoto M, Yamamoto K, Takahashi T, Kuno M, Nakashima Y, Koh H, Nakane T, Hino M, Nakamae H. [Successful treatment with rituximab in acute disseminated encephalomyelitis with whole spinal cord involvement following HLA haploidentical transplantation]. Rinsho Ketsueki. 2018;59(12):2588-2593. Japanese. doi: 10.11406/rinketsu.59.2588. PMID: 30626794.
41. AbdelRazek M, Stone JH. Neurologic Features of Immunoglobulin G4-Related Disease. Rheum Dis Clin North Am. 2017 Nov;43(4):621-631. doi: 10.1016/j.rdc.2017.06.010. PMID: 29061247.
42 Pan JJ, Zhao Y-Y, Lu C, Hu Y-H, Yang Y. Mild encephalitis/encephalopathy with a reversible splenial lesion: five cases and a literature review. Neurol Sci. 2015;36(11):2043 –51.